Title | Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma-A Real-World Multicenter Study (RICE-Retro) |
Author | Huang, Shujie1,2; Wu, Hansheng3; Cheng, Chao4; Zhou, Ming5; Xu, Enwu6; Lin, Wanli7; Wang, Guangsuo8; Tang, Jiming1; Ben, Xiaosong1; Zhang, Dongkun1; Xie, Liang1; Zhou, Haiyu1; Chen, Gang1; Zhuang, Weitao1,2; Tang, Yong1; Xu, Fangping9; Du, Zesen10; Xie, Zefeng3; Wang, Feixiang5; He, Zhe6; Zhang, Hai7; Sun, Xuefeng8; Li, Zijun11,12; Sun, Taotao13; Liu, Jianhua14; Yang, Shuhan15; Xie, Songxi16; Fu, Junhui10 ![]() ![]() |
Corresponding Author | Fu, Junhui; Qiao, Guibin |
Publication Years | 2022-07-13
|
DOI | |
Source Title | |
ISSN | 1664-3224
|
Volume | 13 |
Abstract | PurposeThe present study sets out to evaluate the feasibility, safety, and effectiveness of conversion surgery following induction immunochemotherapy for patients with initially unresectable locally advanced esophageal squamous cell carcinoma (ESCC) in a real-world scenario. Materials and MethodsIn this multi-center, real-world study (NCT04822103), patients who had unresectable ESCC disease were enrolled across eight medical centers in China. All patients received programmed death receptor-1 (PD-1) inhibitor plus chemotherapy every 3 weeks for at least two cycles. Patients with significant relief of cancer-related clinical symptoms and radiological responsive disease were deemed surgical candidates. Feasibility and safety profile of immunochemotherapy plus conversion surgery, radiological and pathological tumor responses, as well as short-term survival outcomes were evaluated. Moreover, data of an independent ESCC cohort receiving induction chemotherapy (iC) were compared. ResultsOne hundred and fifty-five patients were enrolled in the final analysis. Esophagectomy was offered to 116 patients, yielding a conversion rate of 74.8%. R0 resection rate was 94%. Among the 155 patients, 107 (69.0%) patients experienced at least one treatment-related adverse event (TRAE) and 45 (29.0%) patients reported grade 3 and above TRAEs. Significant differences in responsive disease rate were observed between iC cohort and induction immunochemotherapy (iIC) cohort [objective response rate: iIC: 63.2% vs. iC: 47.7%, p = 0.004; pathological complete response: iIC: 22.4% vs. iC: 6.7%, p = 0.001). Higher anastomosis fistula rate was observed in the iC group (19.2%) compared with the iIC group (4%). Furthermore, Significantly higher event-free survival was observed in those who underwent conversion surgery. ConclusionOur results supported that conversion surgery following immunochemotherapy is feasible and safe for patients with initially unresectable locally advanced ESCC. Both radiological and pathological response rates were significantly higher in the iIC cohort compared with those in the traditional iC cohort. |
Keywords | |
URL | [Source Record] |
Indexed By | |
Language | English
|
SUSTech Authorship | Others
|
WOS Research Area | Immunology
|
WOS Subject | Immunology
|
WOS Accession No | WOS:000832803100001
|
Publisher | |
Data Source | Web of Science
|
Citation statistics |
Cited Times [WOS]:5
|
Document Type | Journal Article |
Identifier | http://kc.sustech.edu.cn/handle/2SGJ60CL/365011 |
Department | Shenzhen People's Hospital |
Affiliation | 1.Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Thorac Surg, Guangzhou, Peoples R China 2.Shantou Univ Med Coll, Shantou, Peoples R China 3.Shantou Univ, Affiliated Hosp 1, Med Coll, Dept Thorac Surg, Shantou, Peoples R China 4.Sun Yat Sen University, Affiliated Hosp 1, Dept Thorac Surg, Guangzhou, Peoples R China 5.Guangzhou Med Univ, Affiliated Canc Hosp, Dept Thorac Surg, Guangzhou, Peoples R China 6.Gen Hosp Southern Theater Command, Dept Thorac Surg, PLA, Guangzhou, Peoples R China 7.Gaozhou Peoples Hosp, Dept Thorac Surg, Gaozhou, Peoples R China 8.Southern Univ Sci & Technol, Jinan Univ, Shenzhen Peoples Hosp, Affiliated Hosp 1,Shenzhen Inst Resp Dis,Clin Med, Shenzhen, Peoples R China 9.Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Pathol, Lab Med, Guangzhou, Peoples R China 10.Shantou Cent Hosp, Dept Surg Oncol, Shantou, Peoples R China 11.Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Gen Practice, Guangzhou, Peoples R China 12.Guangdong Prov Peoples Hosp, Guangdong Prov Geriatr Inst, Guangdong Acad Med Sci, Guangzhou, Peoples R China 13.Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, WeiLun PET Ctr, Dept Nucl Med, Guangzhou, Peoples R China 14.Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Oncol, Guangzhou, Peoples R China 15.South China Univ Technol, Sch Med, Chron Dis Lab, Guangzhou, Peoples R China 16.Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Radiat Oncol, Guangzhou, Peoples R China 17.Southern Med Univ, Sch Clin Med 2, Guangzhou, Peoples R China |
Recommended Citation GB/T 7714 |
Huang, Shujie,Wu, Hansheng,Cheng, Chao,et al. Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma-A Real-World Multicenter Study (RICE-Retro)[J]. Frontiers in Immunology,2022,13.
|
APA |
Huang, Shujie.,Wu, Hansheng.,Cheng, Chao.,Zhou, Ming.,Xu, Enwu.,...&Qiao, Guibin.(2022).Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma-A Real-World Multicenter Study (RICE-Retro).Frontiers in Immunology,13.
|
MLA |
Huang, Shujie,et al."Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma-A Real-World Multicenter Study (RICE-Retro)".Frontiers in Immunology 13(2022).
|
Files in This Item: | There are no files associated with this item. |
|
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment